OPC-131461

OPC-131461 is an investigational small molecule drug developed by Otsuka Pharmaceutical. It acts as a dual antagonist of the vasopressin V1a (AVPR1A) and V2 (AVPR2) receptors. The drug is being studied primarily for the treatment of heart failure and cardiac edema, particularly in patients with volume overload who have not responded adequately to standard diuretic therapy. By blocking both V1a and V2 vasopressin receptors, OPC-131461 aims to reduce fluid retention and improve symptoms associated with heart failure[1][2][3]. The compound is administered orally and has reached Phase 2 clinical trials for these indications[1][3][4].